Contact
searchSearch
HMP Global
Login
Quiz

Depression Treatment and Sexual Dysfunction

03/04/2024

Related Content

A lab tech handles psilocybin research
FDA Update
FDA Vouchers Fast-Track Psychedelic Drugs for Depression and PTSD – Psych Congress Responds With Expert Briefing
04/29/2026
Brionna Mendoza
Following an April 18 executive order, the US Food and Drug Administration (FDA) announced new regulatory actions to accelerate the development of psychedelic-assisted therapy for mental health conditions.
Following an April 18 executive order, the US Food and Drug Administration (FDA) announced new regulatory actions to accelerate the development of psychedelic-assisted therapy for mental health conditions.
Following an April 18 executive...
04/29/2026
Psych Congress Network
Philip Gehrman, PhD, CBSM, FAASM
Videos
Targeting Sleep to Improve Mental Health Outcomes
04/08/2026
Philip Gehrman, PhD
Psych Congress Steering Committee Partner Philip Gehrman, PhD, CBSM, FAASM, discusses how targeting sleep may improve outcomes for patients with co-occurring sleep and psychiatric disorders.
Psych Congress Steering Committee Partner Philip Gehrman, PhD, CBSM, FAASM, discusses how targeting sleep may improve outcomes for patients with co-occurring sleep and psychiatric disorders.
Psych Congress Steering...
04/08/2026
Psych Congress Network
A woman lies on the couch holding an ice pack to her head
News
Migraine Nearly Doubles Depression and Anxiety Risk in Cohort Study
03/10/2026
Brionna Mendoza
Patients with migraine are at 2 times the risk for depression or anxiety compared to those without migraine, according to a large nationwide Swedish cohort study published in The Journal of Headache and Pain.
Patients with migraine are at 2 times the risk for depression or anxiety compared to those without migraine, according to a large nationwide Swedish cohort study published in The Journal of Headache and Pain.
Patients with migraine are at 2...
03/10/2026
Psych Congress Network
A man asleep in bed
News
Actigraphy Measures of Sleep and Daily Activity May Forecast Depression Relapse
02/13/2026
Brionna Mendoza
A new multicenter observational cohort study showed that sleep phase variability and daily activity amplitude measured through actigraphy were associated with risk of depression relapse.
A new multicenter observational cohort study showed that sleep phase variability and daily activity amplitude measured through actigraphy were associated with risk of depression relapse.
A new multicenter observational...
02/13/2026
Psych Congress Network

NEW FROM THE NP INSTITUTE ONLINE LEARNING HUB

andrew and julie
Rapid Refresh
Navigating Bipolar Disorder Treatment: Exploring the Role of Second-Generation Antipsychotics
04/11/2024

Featuring Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN

Featuring Andrew Penn, MS, PMHNP...
Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, explore the nuanced role of second-generation antipsychotics in bipolar disorder treatment. They discuss the complexities of managing mania and depression phases and...
Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, explore the nuanced role of second-generation antipsychotics in bipolar disorder treatment. They discuss the complexities of managing mania and depression phases and...
Andrew Penn, MS, PMHNP, and...
04/11/2024
Psych Congress NP Institute
Amber Hoberg
Rapid Refresh
Long-Acting Injectables for Adolescents With Schizophrenia and Schizoaffective Disorder
04/10/2024
Amber Hoberg, MSN, APRN, PMHNP-BC
Amber Hoberg, PMHNP-BC, navigates the complexities of adolescent psychosis treatment, exploring the potential benefits and considerations of LAIs for schizophrenia and schizoaffective disorder, while emphasizing evidence-based practice for...
Amber Hoberg, PMHNP-BC, navigates the complexities of adolescent psychosis treatment, exploring the potential benefits and considerations of LAIs for schizophrenia and schizoaffective disorder, while emphasizing evidence-based practice for...
Amber Hoberg, PMHNP-BC,...
04/10/2024
Psych Congress NP Institute
Hoberg and Matthews
Clinical Insights
Tolerability Testing in Long-Acting Injectable Prescriptions
04/03/2024
Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.
Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.
Do clinicians need to test for...
04/03/2024
Psych Congress NP Institute

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use